Sign in

Trial result ·

Bilevel Positive Airway Pressure and Continuous Albuterol for Pediatric Asthma Exacerbations: A Randomized Clinical Trial.

Written based on 1 research study on PubMed, searched on 5 Nov 2026.

What was studied

This trial tested bilevel positive airway pressure, or BPAP, in children with asthma attacks. It took place in one hospital emergency department. Children aged 5 to 17 had moderate asthma and were on continuous albuterol. They were chosen at random to get BPAP or sham BPAP for 4 hours. Neither staff nor families knew which. The main outcome was how long albuterol was needed.

What they found

With BPAP, children got a mean of 8.3 hours of albuterol. With sham BPAP it was 8.7 hours. The difference was -0.5 hours. The range was -5.0 to 4.1 (P = .84). The trial was stopped at the interim check because it met the bounds for futility. No deaths, invasive ventilation, air leak or aspiration pneumonia occurred in either group.

What it means for patients

The authors conclude that early BPAP gave no clinically significant drop in albuterol time. This was in children with moderate asthma attacks. They say more open-label studies in more severe asthma are required.

Why it is not certain yet

The trial took place at one center. It was stopped early for futility. It covered only moderate asthma. More severe asthma was not studied.

The registered trial

The paper names this trial from a public trial registry. Its page shows who the trial is for, its sites and its status.

Source

Bilevel Positive Airway Pressure and Continuous Albuterol for Pediatric Asthma Exacerbations: A Randomized Clinical Trial.

PubMed · PMID 42646841

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Asthma publications